This MedLibrary.org supplementary page on Radiopharmaceutical is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Radiopharmacology is the study and preparation of radiopharmaceuticals, which are radioactive pharmaceuticals. Radiopharmaceuticals are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases. Many radiopharmaceuticals use technetium (Tc-99m). In the book Technetium by Klaus Schwochau, 31 different radiopharmaceuticals based on Tc-99m are listed for imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors.
A list of nuclear medicine radiopharmaceuticals follows. Some radioisotopes* are used in ionic or inert form without attachment to a pharmaceutical, these are also included. There is a section for each radioisotope with a table of radiopharmaceuticals using that radioisotope. The sections are ordered alphabetically by the English name of the radioisotope. Sections for the same element are then ordered by atomic mass number.
- Not all radionuclides, the radioactive portion of a radiopharmaceutical, are technically "isotopes" despite commonly referred to as such (see isotope).
Calcium-47
47Ca is a beta and gamma emitter.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Ca-47-Ca2+ | Bone metabolism | IV | In-vitro
Not all radionuclides, the radioactive portion of a radiopharmaceutical, are technically "isotopes". Although, they are commonly referred to as such. (SEE Isotope} |
Non-imaging |
Carbon-11
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| C11-L-methyl-methionine | Brain tumour imaging Parathyroid imaging |
IV | In-vivo | Imaging |
Carbon-14
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| C14-Glycocholic acid | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
| C14-PABA (para-amino benzoic acid) | Pancreatic studies | Oral | In-vitro | Non-imaging |
| C14-Urea | Breath test to detect Helicobacter pylori | Oral | In-vitro | Non-imaging |
| C14-d-xylose | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
Chromium-51
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Cr51-Red blood cells | Red cell volume; sites of sequestration; gastrointestinal blood loss | IV | In-vitro | Non-imaging |
| Cr51-Cr3+ | Gastrointestinal protein loss | IV | In-vitro | Non-imaging |
| Cr51-EDTA (ethylenediaminetetraacetic acid) | Glomerular filtration rate measurement | IV | In-vitro | Non-imaging |
Cobalt-57
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Co57-Cyanocobalamin (vitamin B12) | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Cobalt-58
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Co58-Cyanocobalamin (vitamin B12) | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Erbium-169
| Name | Treatment of | Route of administration |
|---|---|---|
| Er169-Colloid | Arthritic conditions | Intra-articular |
Fluorine-18
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| F18-FDG (Fluorodeoxyglucose) | Tumour imaging Myocardial imaging |
IV | In-vivo | Imaging |
| F18-Fluoride | Bone imaging | IV | In-vivo | Imaging |
Gallium-67
67Ga is a gamma emitter. See Gallium scan.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Ga67-Ga3+ | Tumour imaging | IV | In-vivo | Imaging |
| Ga67-Ga3+ | Infection/inflammation imaging | IV | In-vivo | Imaging |
Hydrogen-3
3H or tritium is a beta emitter.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| H3-water | Total body water | Oral or IV | In-vitro | Non-imaging |
Indium-111
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| In111-DTPA (diethylenetriaminepenta-acetic acid) | GI transit | Oral | In-vivo | Imaging |
| In111-DTPA (diethylenetriaminepenta-acetic acid) | Cisternography | Intra-cisternal | In-vivo | Imaging |
| In111-Leucocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
| In111-Platelets | Thrombus imaging | IV | In-vivo | Imaging |
| In111-Pentetreotide | Somatostatin receptor imaging | IV | In-vivo | Imaging |
Iodine-123
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| I123-Iodide | Thyroid uptake | Oral or IV | In-vivo | Non-imaging |
| I123-Iodide | Thyroid imaging Thyroid metastases imaging |
Oral or IV | In-vivo | Imaging |
| I123-o-Iodohippurate | Renal imaging | IV | In-vivo | Imaging |
| I123-MIBG (m-iodobenzylguanidine) | Neuroectodermal tumour imaging | IV | In-vivo | Imaging |
| I123-FP-CIT | SPECT imaging of Parkinson's Disease | IV | In-vivo | Imaging |
Iodine-131
131I is a beta and gamma emitter.
Diagnostic
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| I131-Iodide | Thyroid uptake | Oral | In-vivo | Non-imaging |
| I131-Iodide | Thyroid metastases imaging | Oral or IV | In-vivo | Imaging |
| I131-MIBG (m-iodobenzylguanidine) | Neuroectodermal tumour imaging | IV | In-vivo | Imaging |
Therapeutic
| Name | Treatment of | Route of administration |
|---|---|---|
| I131-Iodide | Thyrotoxicosis | IV or Oral |
| I131-Iodide | Non-toxic goitre | IV or Oral |
| I131-Iodide | Thyroid carcinoma | IV or Oral |
| I131-MIBG (m-iodobenzylguanidine) | Malignant disease | IV |
Iron-59
59Fe is a beta and gamma emitter.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Fe59-Fe2+ or Fe3+ | Iron metabolism | IV | In-vitro | Non-imaging |
Krypton-81m
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Kr81m-Gas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
| Kr-81m-Aqueous solution | Lung perfusion imaging | IV | In-vivo | Imaging |
Nitrogen-13
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| N13-Ammonia | Myocardial blood flow imaging | IV | In-vivo | Imaging |
Oxygen-15
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| O15-Water | Cerebral blood flow imaging Myocardial blood flow imaging |
IV bolus | In-vivo | Imaging |
Phosphorus-32
| Name | Treatment of | Route of administration |
|---|---|---|
| P32-Phosphate | Polycythemia and related disorders | IV or Oral |
Samarium-153
153Sm is a beta and gamma emitter.
| Name | Treatment of | Route of administration |
|---|---|---|
| Sm153-EDTMP (Ethylenediaminotetramethylenephosphoric acid) | Bone metastases | IV |
Selenium-75
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Se75-Selenorcholesterol | Adrenal gland imaging | IV | In-vivo | Imaging |
| Se75-SeHCAT (23-Seleno-25-homo-tauro-cholate) | Bile salt absorption | Oral | In-vivo | Imaging |
Sodium-22
22Na is a positron and gamma emitter.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Na22-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
Sodium-24
24Na is a beta and gamma emitter.
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Na24-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
Strontium-89
| Name | Treatment of | Route of administration |
|---|---|---|
| Sr89-Chloride | Bone metastases | IV |
Technetium-99m
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Tc99m-pertechnetate | Thyroid uptake and thyroid imaging Stomach and salivary gland imaging |
IV | In-vivo | Imaging |
| Tc99m-pertechnetate | Lacrimal imaging | Eye drops | In-vivo | Imaging |
| Tc99m-Human albumin | Cardiac blood pool imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin | Peripheral vascular imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging with venography | IV | In-vivo | Imaging |
| Tc99m-Phosphonates and phosphates | Bone imaging | IV | In-vivo | Imaging |
| Tc99m-Phosphonates and phosphates | Myocardial imaging | IV | In-vivo | Imaging |
| Tc99m-DTPA (diethylenetriaminepenta-acetic acid) | Renal imaging First pass blood flow studies Brain imaging |
IV | In-vivo | Imaging |
| Tc99m-DTPA (diethylenetriaminepenta-acetic acid) | Lung ventilation imaging | Aerosol inhalation | In-vivo | Imaging |
| Tc99m-DMSA(V) (dimercaptosuccinic acid) | Tumour imaging | IV | In-vivo | Imaging |
| Tc99m-DMSA(III) (dimercaptosuccinic acid) | Renal imaging | IV | In-vivo | Imaging |
| Tc99m-Colloid | Bone marrow imaging GI Bleeding |
IV | In-vivo | Imaging |
| Tc99m-Colloid | Lymph node imaging | Interstitial | In-vivo | Imaging |
| Tc99m-Colloid | Oesophageal transit and reflux imaging | Oral | In-vivo | Imaging |
| Tc99m-Colloid | Lacrimal imaging | Eye drops | In-vivo | Imaging |
| Tc99m-HIDA (Hepatic iminodiacetic acid) | Functional biliary system imaging | IV | In-vivo | Imaging |
| Tc99m-Denatured red bood cells | Red cell volume | IV | In-vitro | Non-imaging |
| Tc99m-Red blood cells | GI bleeding Cardiac blood pool imaging |
IV | In-vivo | Imaging |
| Tc99m-MAG3 (mercaptoacetyltriglycine) | Renal imaging First pass blood flow imaging |
IV | In-vivo | Imaging |
| Tc99m-HMPAO (Hexamethyl-propylene amine oxime) | Cerebral blood flow imaging | IV | In-vivo | Imaging |
| Tc99m-HMPAO (Hexamethyl-propylene amine oxime) labelled leucocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Sestamibi | Parathyroid imaging Non-specific tumour imaging |
IV | In-vivo | Imaging |
| Tc99m-Sulesomab (IMMU-MN3 murine Fab'-SH antigranulocyte monoclonal antibody fragments) | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Technegas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
| Tc99m-Human immunoglobulin | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Tetrofosmin | Parathyroid imaging Myocardial imaging |
IV | In-vivo | Imaging |
| Tc99m-ECD (ethyl cysteinate dimer) | Brain imaging | IV | In-vivo | Imaging |
Thallium-201
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Tl201-Tl+ | Non-specific tumour imaging Thyroid tumour imaging |
IV | In-vivo | Imaging |
Xenon-133
| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
|---|---|---|---|---|
| Xe133-gas | Lung ventilation studies | Inhalation | In-vivo | Imaging |
| Xe133 in isotonic sodium chloride solution | Cerebral blood flow | IV | In-vivo | Imaging |
Yttrium-90
| Name | Treatment of | Route of administration |
|---|---|---|
| Y90-Silicate | Arthritic conditions | Intra-articular |
| Y90-Silicate | Malignant disease | Intracavitary |
References
- Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of radioactive substances advisory committee. December 1998. Produced by the National Radiological Protection Board.
- Malabsorption. In: The Merck Manual of Geriatrics, chapter 111.
- Leukoscan summary of product characteristics (Tc99m-Sulesomab).
- Schwochau, Klaus. Technetium. Wiley-VCH (2000). ISBN 3-527-29496-1
Wikipedia content modification information:
- This page was last modified on 24 October 2008, at 08:34.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Radiopharmaceutical".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.
